Breaking News
May 3, 2019 - Vaping and Smoking May Signal Greater Motivation to Quit
May 3, 2019 - Dementia looks different in brains of Hispanics
May 3, 2019 - Short-Staffed Nursing Homes See Drop In Medicare Ratings
May 3, 2019 - Study of teens with eating disorders explores how substance users differ from non-substance users
May 3, 2019 - Scientists develop new video game that may help in the study of Alzheimer’s
May 3, 2019 - Arc Bio introduces Galileo Pathogen Solution product line at ASM Clinical Virology Symposium
May 3, 2019 - Cornell University study uncovers relationship between starch digestion gene and gut bacteria
May 3, 2019 - How to Safely Use Glucose Meters and Test Strips for Diabetes
May 3, 2019 - Anti-inflammatory drugs ineffective for prevention of Alzheimer’s disease
May 3, 2019 - Study tracks Pennsylvania’s oil and gas waste-disposal practices
May 3, 2019 - Creating a better radiation diagnostic test for astronauts
May 3, 2019 - Vegans are often deficient in these four nutrients
May 3, 2019 - PPDC announces seed grants to develop medical devices for children
May 3, 2019 - Study maps out the frequency and impact of water polo head injuries
May 3, 2019 - Research on Reddit identifies risks associated with unproven treatments for opioid addiction
May 3, 2019 - Good smells may help ease tobacco cravings
May 3, 2019 - Medical financial hardship found to be very common among people in the United States
May 3, 2019 - Researchers develop multimodal system for personalized post-stroke rehabilitation
May 3, 2019 - Study shows significant mortality benefit with CABG over percutaneous coronary intervention
May 3, 2019 - Will gene-editing of human embryos ever be justifiable?
May 3, 2019 - FDA Approves Dengvaxia (dengue vaccine) for the Prevention of Dengue Disease in Endemic Regions
May 3, 2019 - Why Tonsillitis Keeps Coming Back
May 3, 2019 - Fighting the opioid epidemic with data
May 3, 2019 - Maggot sausages may soon be a reality
May 3, 2019 - Deletion of ATDC gene prevents development of pancreatic cancer in mice
May 2, 2019 - Targeted Therapy Promising for Rare Hematologic Cancer
May 2, 2019 - Alzheimer’s disease is a ‘double-prion disorder,’ study shows
May 2, 2019 - Reservoir bugs: How one bacterial menace makes its home in the human stomach
May 2, 2019 - Clinical, Admin Staff From Cardiology Get Sneak Peek at Epic
May 2, 2019 - Depression increases hospital use and mortality in children
May 2, 2019 - Vicon and NOC support CURE International to create first gait lab in Ethiopia
May 2, 2019 - Researchers use 3D printer to make paper organs
May 2, 2019 - Viral infection in utero associated with behavioral abnormalities in offspring
May 2, 2019 - U.S. Teen Opioid Deaths Soaring
May 2, 2019 - Opioid distribution data should be public
May 2, 2019 - In the Spotlight: “I’m learning every single day”
May 2, 2019 - 2019 Schaefer Scholars Announced
May 2, 2019 - Podcast: KHN’s ‘What The Health?’ Bye-Bye, ACA, And Hello ‘Medicare-For-All’?
May 2, 2019 - Study describes new viral molecular evasion mechanism used by cytomegalovirus
May 2, 2019 - SLU study suggests a more equitable way for Medicare reimbursement
May 2, 2019 - Scientists discover first gene involved in lower urinary tract obstruction
May 2, 2019 - Researchers identify 34 genes associated with increased risk of ovarian cancer
May 2, 2019 - Many low-income infants receive formula in the first few days of life, finds study
May 2, 2019 - Global study finds high success rate for hip and knee replacements
May 2, 2019 - Taking depression seriously: What is it?
May 2, 2019 - With Head Injuries Mounting, Will Cities Put Their Feet Down On E-Scooters?
May 2, 2019 - Scientists develop small fluorophores for tracking metabolites in living cells
May 2, 2019 - Study casts new light into how mothers’ and babies’ genes influence birth weight
May 2, 2019 - Researchers uncover new brain mechanisms regulating body weight
May 2, 2019 - Organ-on-chip systems offered to Asia-Pacific regions by Sydney’s AXT
May 2, 2019 - Adoption of new rules drops readmission penalties against safety net hospitals
May 2, 2019 - Kids and teens who consume zero-calorie sweetened beverages do not save calories
May 2, 2019 - Improved procedure for cancer-related erectile dysfunction
May 2, 2019 - Hormone may improve social behavior in autism
May 2, 2019 - Alzheimer’s disease may be caused by infectious proteins called prions
May 2, 2019 - Even Doctors Can’t Navigate Our ‘Broken Health Care System’
May 2, 2019 - Study looks at the impact on criminal persistence of head injuries
May 2, 2019 - Honey ‘as high in sugars as table sugar’
May 2, 2019 - Innovations to U.S. food system could help consumers in choosing healthy foods
May 2, 2019 - FDA Approves Mavyret (glecaprevir and pibrentasvir) as First Treatment for All Genotypes of Hepatitis C in Pediatric Patients
May 2, 2019 - Women underreport prevalence and intensity of their own snoring
May 2, 2019 - Concussion summit focuses on science behind brain injury
May 2, 2019 - Booker’s Argument For Environmental Justice Stays Within The Lines
May 2, 2019 - Cornell research explains increased metastatic cancer risk in diabetics
May 2, 2019 - Mount Sinai study provides fresh insights into cellular pathways that cause cancer
May 2, 2019 - Researchers to study link between prenatal pesticide exposures and childhood ADHD
May 2, 2019 - CoGEN Congress 2019: Speakers’ overviews
May 2, 2019 - A new strategy for managing diabetic macular edema in people with good vision
May 2, 2019 - Sagent Pharmaceuticals Issues Voluntary Nationwide Recall of Ketorolac Tromethamine Injection, USP, 60mg/2mL (30mg per mL) Due to Lack of Sterility Assurance
May 2, 2019 - Screen time associated with behavioral problems in preschoolers
May 2, 2019 - Hormone reduces social impairment in kids with autism | News Center
May 2, 2019 - Researchers synthesize peroxidase-mimicking nanozyme with low cost and superior catalytic activity
May 2, 2019 - Study results of a potential drug to treat Type 2 diabetes in children announced
May 2, 2019 - Multigene test helps doctors to make effective treatment decisions for breast cancer patients
May 2, 2019 - UNC School of Medicine initiative providing unique care to dementia patients
May 2, 2019 - Nestlé Health Science and VHP join forces to launch innovative COPES program for cancer patients
May 2, 2019 - Study examines how our brain generates consciousness and loses it during anesthesia
May 2, 2019 - Transition Support Program May Aid Young Adults With Type 1 Diabetes
May 2, 2019 - Study shows how neutrophils exacerbate atherosclerosis by inducing smooth muscle-cell death
May 2, 2019 - Research reveals complexity of how we make decisions
Scientists develop new class of compounds for treatment of progressive neurodegenerative disorder

Scientists develop new class of compounds for treatment of progressive neurodegenerative disorder

St. Jude Children’s Research Hospital investigators have developed a new class of compounds that extended the lives and eased symptoms of mice with a progressive neurodegenerative human disorder. The findings appear today in the journal Nature Communications.

The rare, inherited disorder, pantothenate kinase-associated neurodegeneration (PKAN), affects up to three in a million individuals and is caused by mutations in the PANK2 gene. Iron accumulates in brain cells, and patients have difficulty walking, swallowing, chewing and performing other activities. There is no treatment.

PKAN is thought to occur when neurons lack an adequate supply of the molecule coenzyme A (CoA), preventing them from functioning normally. PANK2 is one of three closely related proteins (isoforms) that regulate CoA production.

“We have developed a class of small molecules called pantazines that penetrate the blood-brain barrier and elevate CoA levels using a novel mechanism,” said senior author Suzanne Jackowski, Ph.D., a member of the St. Jude Department of Infectious Diseases.

St. Jude has patented the pantazines and their use for treatment of PKAN and related CoA disorders. The hospital has licensed the compounds to CoA Therapeutics of Palo Alto, CA, which has begun planning clinical trials.

The start

CoA is a helper molecule essential for carbohydrate and fat metabolism. “Just like things go wrong when oil in your car gets low, problems develop in cells when levels of CoA get low,” said corresponding author Charles Rock, Ph.D., a member of the St. Jude Infectious Diseases department. CoA also plays a role in epigenetic regulation of gene expression, which is disrupted in many cancers.

Jackowski has studied CoA production (biosynthesis) and PANK for decades. In 1981, shortly after she and Rock joined St. Jude, they published evidence that PANK was a pivotal regulator of CoA production in bacteria.

Then in 2001, research led by Oregon Health and Science University investigators reported that mutations in PANK2 were associated with the neurodegenerative disorder that came to be known as PKAN. Before long, Jackowski was invited to the annual conference of a patient advocacy group and met individuals and families affected by the disorder.

“After that, Chuck and I were walking back from lunch in the St. Jude cafeteria one day and I raised the possibility of treating this devastating disease by stimulating or activating an alternative pantothenate kinase to make up for the CoA deficiency.” Jackowski said. She was referring to the PANK1 or PANK3 enzymes that can also trigger CoA synthesis. “That’s when we launched the side project that led us to pantazines.”

The search

The researchers joined forces with colleagues in the St. Jude departments of Structural Biology and Chemical Biology and Therapeutics.

Co-author Richard Lee, Ph.D., and others in Chemical Biology and Therapeutics, carefully crafted the pantazines based on a compound first identified in a screen of the hospital’s library of more than 500,000 drugs and small molecules. The pantazines were carefully optimized to increase cellular CoA levels, cross the blood-brain barrier to reach the affected neurons, work as a pill, and have minimal side effects to become a novel drug candidate for PKAN treatment.

As researchers analyzed possible drug candidates, co-authors Stephen White, D.Phil., and Mi-Kyung Yun of the St. Jude Structural Biology department captured images of candidate compounds bound to PANK to guide compound optimization. The image showed the compound, PZ-2891, bound to the protein structure in a unique way to temporarily lock PANK in the “on” position to promote CoA production.

The evidence

In the laboratory, CoA levels increased in cells treated with PZ-2891. Levels also increased in the brains of normal mice as well as mice St. Jude researchers developed to model PKAN in humans. The treated mice lived longer, grew more normally and resumed walking. There were no apparent side effects.

“Science helps us understand how to do medicine,” Rock said. “Reading that paper in 1981 about regulation of CoA biosynthesis in E. coli you might have wondered, who cares? But basic research is what made this discovery possible.”

Jackowski said, “As a basic scientist, you always have the hope in the back of your mind that something you do will reach the clinic and make a difference in peoples’ lives. I feel fortunate to be where we are in this project.

“We were lucky to be at St. Jude where we are all on a mission to help children with catastrophic diseases and have been given the resources and colleagues necessary to tackle challenging diseases such as PKAN,” she said.

Tagged with:

About author

Related Articles